NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization300.19 mln
Float38.87 mln
Earnings Date08/06/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.51
Likely manipulated
1-Year Forecast
12.11
Transformational upside
Relative Strength
23
/ 100
Significantly lagging
Debt / Equity
0.03
Debt-free
ROE
-34.31
Deeply negative
Business Description
Founded in 2009 and based in Cambridge, UK, Bicycle Therapeutics is a clinical-stage drug developer working on a new category of precision medicines designed to treat cancers and other serious conditions that current therapies struggle to address. The company has built a pipeline of targeted treatments, including several compounds in active clinical trials aimed at specific tumor types, as well as early-stage programs focused on neurological and neuromuscular diseases. Bicycle Therapeutics works alongside a number of established pharmaceutical companies, including Novartis, AstraZeneca, Bayer, Ionis Pharmaceuticals, and Genentech, to advance treatments across multiple disease areas.
